Annamycin safety: Moleculin (NASDAQ: MBRX) sees no cardiotoxicity
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Moleculin Biotech, Inc. filed a current report to furnish a press release about new safety information for its investigational drug Annamycin. The company states that an independent assessment confirmed no cardiotoxicity of Annamycin in 90 subjects, addressing an important safety consideration related to potential effects on the heart. The press release is included as Exhibit 99.1 and is furnished under Item 7.01, meaning it is provided for information purposes and is not treated as filed under securities law requirements.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 7.01, 9.01
2 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): January 13, 2026
(Exact Name of Registrant as Specified in its Charter)
|
|
|
|
|
(State or Other Jurisdiction of
Incorporation or Organization)
|
(Commission File No.)
|
(I.R.S. Employer Identification
No.)
|
(Address of principal executive offices and zip code)
(713 ) 300-5160
(Registrant’s telephone number, including area code)
(Former name or former address, if changed from last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol (s)
|
Name of each exchange on which registered
|
|
|
|
The
|
|
Item 7.01
|
Regulation FD Disclosure
|
On January 13, 2026, Moleculin Biotech, Inc. (the “Company”), issued a press release announcing the Company reports independent assessment confirms no cardiotoxicity of Annamycin in 90 subjects.
A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference herein.
The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be “filed” for the purpose of the Securities Exchange Act of 1934, as amended (“Exchange Act”), nor shall it be incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (“Securities Act”), unless specifically identified therein as being incorporated by reference.
|
Item 9.01
|
Financial Statements and Exhibits.
|
|
(d)
|
Exhibits.
|
|
Exhibit
No.
|
Description
|
|
99.1
|
Press Releasedated January 13, 2026
|
|
104
|
Cover page Interactive Data File (formatted as Inline XBRL document)
|
SIGNATURE
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
MOLECULIN BIOTECH, INC.
|
|||
|
Date:
|
January 13, 2026
|
||
|
By:
|
/s/ Jonathan P. Foster
|
||
|
Jonathan P. Foster
|
|||
FAQ
What did Moleculin Biotech (MBRX) report in this 8-K filing?
The company furnished a press release stating that an independent assessment confirmed no cardiotoxicity of its drug candidate Annamycin in 90 subjects.
Which Moleculin Biotech drug is discussed in the January 13, 2026 report?
The report focuses on Annamycin, an investigational drug for which an independent assessment found no cardiotoxicity in 90 subjects.
How many subjects were included in the Annamycin cardiotoxicity assessment reported by MBRX?
The company states that the independent assessment of Annamycin’s cardiotoxicity covered 90 subjects and found no cardiotoxicity.
How is the Annamycin cardiotoxicity update provided in Moleculin Biotech’s 8-K?
The update is provided through a press release attached as Exhibit 99.1, which is furnished under Item 7.01 and not treated as filed under the Exchange Act.
Does the Moleculin Biotech (MBRX) 8-K include the full details of the Annamycin assessment?
The 8-K states that details are in the press release attached as Exhibit 99.1, which is incorporated by reference in the report.